News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Grafix® Manuscript From Osiris Therapeutics, Inc. (OSIR)’ Multi-center, Randomized, Controlled Clinical Trial Available Electronically In Peer-Reviewed Journal



7/23/2014 12:21:34 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to control in patients with chronic diabetic foot ulcers (DFUs), which was accepted for publication in the International Wound Journal, is now available online and will also be in an upcoming issue.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES